Our Mission-Driven Company
Proove Genomics is a molecular diagnostics company delivering on the promise of precision pain medicine based on its award-winning history and research. Proove performs advanced laboratory testing in its CLIA-certified laboratory, and then analyzes that information, along with a patient’s phenotypic factors such as age, gender, ethnicity, and clinically-validated assessments of physical function, mental health, and quality of life using advanced mathematical algorithms, to develop and deliver unique profiles to better understand and improve the treatment of pain. Our research has been published in peer-reviewed journals and recognized by leading medical societies such as the American Academy of Pain Medicine, American Society of Interventional Pain Physicians, American Academy of Neurology, American Society of Regional Anesthesia, American Academy of Addiction Medicine, and more. Proove operates a state-of-the-art CLIA-certified laboratory in Houston, Texas near the world’s largest life sciences destination – the Texas Medical Center – with 8 different academic and research institutions, not to mention the 21 different hospitals. Proove also has offices in Irvine, California, and Orem, Utah.
Our Passionate Servant Leaders
Lisa Beggs, Chief People Officer
Khanh Nguyen, Chief Technology Officer
Eric Fronk, Chief Financial Officer
Senior Certified Professional HR Executive who is the former Director of HR at Proove. Former SVP of HR for various organizations ranging from healthcare to construction. At Proove, she built the HR department, training, and processes.
Eric Fronk, Chief Financial Officer
Khanh Nguyen, Chief Technology Officer
Eric Fronk, Chief Financial Officer
Financial & operational leader with Big-4 accounting experience. Served as CFO & COO, leading early-stage growth and later-stage expansion. Led multiple fund-raising efforts and IPO processes in healthcare, medical device, SaaS, and biotech.
Brian Meshkin, Executive Chairman
Khanh Nguyen, Chief Technology Officer
Khanh Nguyen, Chief Technology Officer
Founder of Proove, award-winning entrepreneur and CEO, inventor of Proove IP, social entrepreneur and impact investor, published pain researcher in top 15% in the world, over 25 years of experience in pharmaceuticals and diagnostics
Khanh Nguyen, Chief Technology Officer
Khanh Nguyen, Chief Technology Officer
Khanh Nguyen, Chief Technology Officer
Over 25 years’ as a CTO and CIO. Former CTO of Proove, led the team that built the cloud-based technology responsible for collecting, analyzing, and storing the world's largest clinical-genetic database for chronic pain.
Milind Patel, MD; Chief Medical Officer
Tricia Schumann, Chief Communications Officer
Tricia Schumann, Chief Communications Officer
Double board-certified pain management specialist and physiatrist, with a special fellowship in Healthcare Quality Improvement and Clinical Safety at the University of Pennsylvania School of Medicine.
Tricia Schumann, Chief Communications Officer
Tricia Schumann, Chief Communications Officer
Tricia Schumann, Chief Communications Officer
Over three decades of experience in leadership and ownership of hyper- growth businesses, healthcare focus in the past 15 years. Former Chief Marketing Officer for Arches Health Plan (ACO) and serves on the Board of Centura Health (Salt Lake Regional Medical Center).
Mark Wilig, Chief Commercial Officer
Tricia Schumann, Chief Communications Officer
Mark Wilig, Chief Commercial Officer
A strong business leader who has built global businesses through growing organizations to drive exponential growth as Chief Commercial Officer or in senior commercial roles with Thermo Fisher, Abbott CardioDx, PrognostiX, Exiqon, and Specialty Labs.
Our History: David Defeating Goliath
2009-2018 - Pioneer of Personalized Pain Medicine
Founded in the depths of the Great Recession, award-winning social entrepreneur Brian Meshkin had a vision of how to deliver on the promise of personalized medicine for chronic pain patients and also help solve the opioid overdose crisis. After 18 months of R&D, the first profile was invented and commercialized in the summer of 2011. Over the next few years, Proove Biosciences would become one of North America’s fastest growing technology companies, listed on the Inc. 500 (#323) and the Deloitte Technology Fast500 (#69). With award-winning research from leading medical societies, including the American Society of Interventional Pain Physicians, American Academy of Neurology, American Society of Regional Anesthesia, and American Academy of Addiction Medicine, Proove pioneered the field of precision pain medicine, tested over 200,000 patients, and ultimately employed over 300 amazing employees, collaborated with leading research institutions including UNC Chapel Hill, the University of Utah, USC, McGill University, National Spine & Pain Center, and more. With $30 million in annual revenue, profitability and years of audited financial statements, the Company was preparing for an IPO and to become the standard of care with its life-saving technologies.
2018-2022 - Misinformation Destruction & Vindication
Instead of conducting an IPO in 2017, Proove was derailed due to erroneous allegations of wrongdoing. Starting with two whistleblower lawsuits filed by terminated employees that were not accepted by the federal government and dismissed, these false allegations were then maliciously and knowingly published by the website STAT News. In May 2017, the U.S. Attorney’s office in San Diego began a five-year process of violating federal laws and other policies, including falsifying evidence, violating attorney-client privilege, and other numerous illegalities which resulted in the destruction of Proove Biosciences, the smearing of reputations, 300 employees losing their jobs, and tens of millions of dollars wasted. After all of this prosecutorial misconduct, the DOJ could not find any wrongdoing. Thus, the U.S. Department of Justice submitted a motion in federal court to dismiss all charges against all parties involved “in the interests of justice” because there were no violations of the law. Numerous prosecutors involved in the case were fired, including the lead prosecutor who was Chief of the Fraud Division, in the U.S. Attorney’s office in San Diego. Most of the FBI agents involved in the case had been disqualified by the DOJ due to wrongdoing, and the actual U.S. Attorney in San Diego had to recuse himself. With the vindication at the end of 2022, the unjust “scarlet letter” had been removed from this previous company and all those involved.
Reborn Better to Finish the Mission
With the “800-pound gorilla” removed, Proove’s founder Brian Meshkin counseled about next steps with key opinion leaders in the field, as well as with some members of his former executive team and others who had previously worked with Proove Biosciences years ago. Almost unanimously, everyone urged Brian to find a way to finish the mission and make this life-saving laboratory technology available again. The opioid and chronic pain crises had only worsened since Proove was destroyed in 2017. After a lot of prayer and consideration, Brian founded Proove Genomics in the fall of 2023 with a team of former Proove executives and others wishing to join the mission. He raised a seed capital round led by PFD Capital Partners of Orange County California. This passionate, social impact-focused team is committed to finishing the mission and delivering on the promise of personalized pain treatments. Like pain patients and pain physicians who have been vilified by the government and the media, Proove is proud to have overcome the odds and is committed to saving lives and reducing the many afflictions caused by the nation’s most prevalent and expensive health condition - chronic pain. As Linda McMahon once said, “I have learned it's not how you fall, but how you get up that truly matters.”
